The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

It's been a roller coaster ride for the drug ever since it was granted accelerated approval in 2020 for the treatment of ...

Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...

The Food and Drug Administration on Thursday delivered a split decision to a blood cancer drug from GSK, approving its use in ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination ...

DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...

The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and ...

Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn ...

In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...